<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206568</url>
  </required_header>
  <id_info>
    <org_study_id>PER511</org_study_id>
    <nct_id>NCT02206568</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomised Trial Investigating Pharmacokinetic Properties of Ultra-Rapid-Acting Insulin Lispro (URAL) in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institut f√ºr Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the total pharmacodynamic response of URAL and insulin lispro.&#xD;
&#xD;
      To compare the total pharmacokinetic exposure between URAL and insulin lispro.&#xD;
&#xD;
      To assess the safety and tolerability of URAL and insulin lispro.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of URAL</measure>
    <time_frame>1 day</time_frame>
    <description>Area under the serum insulin lispro concentration-time curve from 0-30 minutes after administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of appearance of serum insulin lispro</measure>
    <time_frame>1 day</time_frame>
    <description>Measurement of time to reach insulin lispro concentration &gt;30 pmol/L in the serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>1 day</time_frame>
    <description>Assessment of safety and tolerability of URAL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>URAL vs. Insulin lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URAL</intervention_name>
    <arm_group_label>URAL vs. Insulin lispro</arm_group_label>
    <other_name>Ultra-Rapid-Acting Insulin Lispro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Male subjects age 18-65 years inclusive&#xD;
&#xD;
          3. Type 1 diabetes mellitus diagnosed clinically &gt;= 12 months&#xD;
&#xD;
          4. Treatment with multiple daily insulin injections or CSII &gt;= 12 months&#xD;
&#xD;
          5. Current total daily insulin treatment &lt;1.2 (I)U/kg/day&#xD;
&#xD;
          6. Current total daily bolus insulin treatment &lt;0.7 (I)U/kg/day&#xD;
&#xD;
          7. Body mass index 18.0-30.0 kg/m2 inclusive&#xD;
&#xD;
          8. HbA1c =&lt;9.0% by local laboratory analysis (one retest within a week is permitted with&#xD;
             the result of the last test being conclusive)&#xD;
&#xD;
          9. C-peptide =&lt; 0.30 nmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to trial products or related products&#xD;
&#xD;
          2. Previous participation in this trial. .&#xD;
&#xD;
          3. Receipt of any non-marketed investigational product within 3 months&#xD;
&#xD;
          4. Clinically significant abnormal haematology, biochemistry, liver enzymes, or&#xD;
             coagulation screening tests&#xD;
&#xD;
          5. Suffer from or history of a life threatening disease or any clinically significant&#xD;
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,&#xD;
             endocrinological, haematological, dermatological, venereal , neurological, psychiatric&#xD;
             diseases or other major disorders&#xD;
&#xD;
          6. History of deep leg vein thrombosis or a frequent appearance of deep leg vein&#xD;
             thrombosis in 1st degree relatives&#xD;
&#xD;
          7. Cardiac problems defined as decompensated heart failure (New York Heart Association&#xD;
             class III and IV) at any time and/or angina pectoris within the last 12 months and/or&#xD;
             acute myocardial infarction at any time.&#xD;
&#xD;
          8. Supine blood pressure at screening outside the range of 90-140 mmHg for systolic or&#xD;
             50-90 mmHg for diastolic . Pulse outside 50 to 90 bpm.&#xD;
&#xD;
          9. Clinically significant abnormal ECG at screening.&#xD;
&#xD;
         10. Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular&#xD;
             autonomic neuropathy.&#xD;
&#xD;
         11. Any disease or condition that, in the opinion of the Investigator, would represent an&#xD;
             unacceptable risk for the subject's safety.&#xD;
&#xD;
         12. Subject positive for HBs-Ag, HCV-Ab&#xD;
&#xD;
         13. Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies, or HIV-1&#xD;
             antigen according to locally used diagnostic testing.&#xD;
&#xD;
         14. History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction.&#xD;
&#xD;
         15. Subject who has donated blood or plasma in the past month or more than 500 mL within 3&#xD;
             months.&#xD;
&#xD;
         16. Surgery or trauma with significant blood loss (more than 500 mL) within 3 months.&#xD;
&#xD;
         17. Current treatment with systemic (oral, IV, or inhaled) corticosteroids, monoamine&#xD;
             oxidase inhibitors, NSAID, prostaglandin blockers, systemic non-selective&#xD;
             beta-blockers, growth hormone (last 3 months), non-routine vitamins or herbal products&#xD;
             (last 2 weeks). Thyroid hormones are not allowed unless the use of these has been&#xD;
             stable during the last 3 months. Routine vitamins are permitted up to 48 hours prior&#xD;
             to dosing.&#xD;
&#xD;
         18. Significant history of alcoholism and/or drug/chemical abuse as per Investigator's&#xD;
             judgement or a positive result in the urine drug/alcohol breath test screen at the&#xD;
             screening visit.&#xD;
&#xD;
         19. Heavy smoker&#xD;
&#xD;
         20. Not able or willing to refrain from smoking and use of nicotine.&#xD;
&#xD;
         21. Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemia event during the last&#xD;
             12 months) or hypoglycaemic unawareness.&#xD;
&#xD;
         22. Subject with mental incapacity or language barriers precluding adequate understanding.&#xD;
&#xD;
         23. Potentially non-compliant or uncooperative during the trial.&#xD;
&#xD;
         24. Any condition that would interfere with trial participation or evaluation of results.&#xD;
&#xD;
         25. No relevant lipodystrophy within the area of drug administration and Doppler&#xD;
             sonography.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alin Stirban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut fur Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut fur Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>phase 1</keyword>
  <keyword>insulin lispro</keyword>
  <keyword>male subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

